Reply to Chu et al., "Adoption of the New CLSI Fluoroquinolone Breakpoints for
Enterobacteriaceae
"
J Clin Microbiol
.
2019 Oct 23;57(11):e01268-19.
doi: 10.1128/JCM.01268-19.
Print 2019 Nov.
Authors
Tam T Van
1
2
,
Emi Minejima
3
,
Chiao An Chiu
3
,
Susan M Butler-Wu
4
Affiliations
1
Department of Pathology, Harbor-UCLA Medical Center, Torrance, California, USA.
2
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
3
Department of Clinical Pharmacy, USC School of Pharmacy, Los Angeles, California, USA.
4
Department of Pathology and Laboratory Medicine, Keck School of Medicine of USC, Los Angeles, California, USA butlerwu@usc.edu.
PMID:
31645412
PMCID:
PMC6813016
DOI:
10.1128/JCM.01268-19
No abstract available
Publication types
Comment
MeSH terms
Enterobacteriaceae Infections*
Enterobacteriaceae*
Fluoroquinolones
Humans
Pseudomonas aeruginosa
Substances
Fluoroquinolones